

Open access • Posted Content • DOI:10.1101/2021.06.08.447308

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies — Source link

Alexandra J. Spencer, Susan J. Morris, Marta Ulaszewska, Claire Powers ...+23 more authors


Institutions: University of Oxford, Institute for Animal Health, Wellcome Trust Centre for Human Genetics, Imperial College London ...+1 more institutions

Published on: 09 Jun 2021 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Original antigenic sin and Booster dose

Related papers:

- ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
- Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
- Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.
- Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
- Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study



The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies

Alexandra J Spencer^{1*}, Susan Morris¹, Marta Ulaszewska¹, Claire Powers¹, Reshma Kailath¹, Cameron Bissett¹, Adam Truby¹, Nazia Thakur^{1,2}, Joseph Newman², Elizabeth R Allen¹, Chang Liu^{3,4}, Wanwisa Dejnirattisai³, Juthathip Mongkolsapaya³, Hannah Davies¹, Francesca R Donnellan¹, David Pulido¹, Thomas P. Peacock⁵, Wendy S. Barclay⁵, Helen Bright⁶, Kuishu Ren⁶, Gavin Screaton³, Patrick McTammy⁶, Dalan Bailey², Sarah C Gilbert¹, Teresa Lambe¹

1 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom

2 The Pirbright Institute, Woking, Surrey, United Kingdom

3 The Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, United Kingdom

4 Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, United Kingdom

5 Department of Infectious Disease, Imperial College London, United Kingdom

6 AstraZeneca, Gaithersburg 20878, Maryland, United States

*Correspondence to: Alexandra J Spencer, The Jenner Institute, ORCRB, Roosevelt Drive, Oxford

OX3 7DQ. Email: alex.spencer@ndm.ox.ac.uk.

Abstract:

There is an ongoing global effort, to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations that negatively impact the role of neutralising antibodies. In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine against the variant of concern B.1.351 (AZD2816). We demonstrate AZD2816 is immunogenic after a single dose and when used as a booster dose in animals primed with original vaccine AZD1222, we see no evidence of original antigenic sin but high titre antibodies against a number of variant spike proteins. In addition, neutralisation titres against B.1.351 (Beta), B.1.617.1 (Kappa) and B.1.617.2 (Delta), are induced in these boost regimens. These data support the ongoing clinical development and testing of this new variant vaccine.

Introduction:

Since the first reports of infections caused by a novel coronavirus, there has been an unprecedented global effort to design, manufacture and test multiple vaccines against SARS-CoV-2. All authorised vaccines, to date, target the full-length spike protein of SARS-CoV-2 and induce neutralising antibodies to varying levels. COVID-19 vaccines are being deployed world-wide and

effectiveness data is now demonstrating the impact vaccination has on preventing COVID related hospital admissions and death ¹⁻³.

Over the course of the pandemic a number of variants of concern (VoC) have been identified, each containing multiple mutations within the viral genome. Variants with mutations in the spike protein and in particular the receptor binding domain (RBD), which facilitates viral cell entry via the angiotensin-converting enzyme 2 (ACE2) receptor, are of most concern. There is the potential for VoC to escape vaccine-induced host immunity due to the reduced ability of neutralising antibodies to bind and prevent cell entry of the VoC, resulting in infection and disease even in vaccinated individuals.

The B.1.351 variant (Beta)⁴, first identified in October 2020, contains 10 changes across the spike protein with 3 amino acid changes in the RBD region. These changes in RBD are reported to increase binding between spike and ACE2, leading to overall reduced ability of antibodies induced against the original virus to block cell entry ⁵. Efforts are underway to produce second generation SARS CoV-2 vaccines targeting VoC.

In this study we describe the generation and preclinical assessment of ChAdOx1 expressing B.1.351 spike protein; AZD2816. Importantly both binding and neutralising antibodies against B.1.351 are measured after single dose vaccination. When AZD2816 is used as a booster dose in mice already primed with the original ChAdOx1 nCoV-19 (AZD1222) we measure strong antibody binding against both the original wild-type and B.1.351 spike protein, with booster doses increasing the antibody response and neutralising ability against other variants. These data support the clinical testing of AZD2816 either alone or in prime-boost regimens with heterologous spike proteins.

Results:

Single dose of vaccine induces cross-reactive immunity.

Following reports of the new SARS-CoV-2 variant B.1.351 expressing multiple mutations across the spike protein and reduced ability of vaccine induced and convalescent sera to neutralise this variant virus ⁵, we generated a new ChAdOx1 vector expressing spike containing the key B.1.351 mutations (Figure 1). To assess the immunogenicity, BALB/c mice were immunised with 10⁸iu AZD1222 (ChAdOx1 nCoV-19), AZD2816 (ChAdOx1 nCoV-19 B.1.351) or with 10⁸iu of each vaccine mixed together prior to immunisation (Figure 2A). Comparable levels of anti-spike antibodies were observed in all groups of vaccinated mice against both wild-type spike and B.1.351 spike protein (Figure 2B). Mixing both vaccines together did not compromise the antibody response to either spike protein, nor was there a difference between total ELISA Units measured on day 9 or day 16 post-vaccination (Figure 2B). This rapid onset of a measurable antibody response suggests this vaccine is highly immunogenic. Neutralising antibodies, measured in pseudotyped virus neutralisation assay, were detected against original wild-type and B.1.351 (Figure 2C).

T cell responses were measured by IFN γ ELISpot with splenocytes stimulated with peptide pools containing peptides common to both vaccines, wild-type spike peptides or B.1.351 peptides (Table S2). Equivalent numbers of IFN γ producing cells were detected against all pools of spike peptides at both timepoints measured (Figure 2D), with responses to the common peptides dominating the response and minimal responses observed against variant regions. Consistent with earlier studies ⁶, the T cell response was dominant towards the first 2 peptide pools corresponding to the S1 portion of the protein (Figure 2E) across all vaccine groups.

To determine whether a booster vaccination with a variant vaccine was impacted in the presence of a response to the wild-type spike protein, mice were immunised with one dose of AZD1222 prior to boosting with AZD2816 and antibody responses compared across relevant groups. Total IgG responses, measured by ELISA, showed that a booster dose of AZD2816 increased the antibody titre against wild-type spike and B.1.351 spike (Figure 3A). In addition, boosting AZD1222 primed mice with AZD2816 increased the antibody titre against other variant proteins including P.1 (Gamma) and B.1.429 (Epsilon) when compared with a single dose of AZD1222 (Figure 3B). Neutralising antibody titres were also higher against the wild-type, B.1.351, B.1.617.1 (Kappa) or B.1.617.2 (Delta) (variants of concern) in two dose regimens with AZD1222 and AZD2816 (Figure 3C and Table 1).

AZD2816 as a third dose maintains T cell responses

To maximise the vaccine induced immune response and associated vaccine efficacy against disease, AZD1222 has been authorised for use in a 2-dose vaccination regimen. To determine the impact of immunisation with AZD2816 after the clinically recommended dosing regimen, BALB/c mice received two doses of AZD1222 4 weeks apart and were boosted with 10⁸ iu of AZD2816 or remained unboosted (Figure 4A). Although a booster dose with AZD2816 did not further increase the frequency of antigen specific T cells (Figure 4B), the breadth of the cellular immune response remained consistent (Figure 4B). The cellular immune response is dominated by responses to common SARS-CoV-2 spike peptides with minimal reactivity against peptides from either original spike WT or B.1.153 as measured after a single dose of vaccine (Figure 2). Most importantly, a third dose vaccination with AZD2816 did not alter T cell response with CD4⁺ T cells shown to produce primarily IFN γ , and no-significant difference in the proportion or number of T effector (Teff), T effector memory (Tem) or T central memory (Tcm) CD4⁺ T cells observed, (Figure 4C). Consistent with previous data in mice ⁶, the anti-spike cell-mediated response was dominated by CD8⁺ T cells, with a high frequency of CD8⁺ T cells producing IFN γ and TNF α was observed in both groups of mice (Figure 4D left), with a response dominated by Teff and Tem CD8⁺ T cells, that was similar between vaccine regimens.

AZD2816 as a third dose can further enhance antibody responses induced by two doses of AZD1222

Antibody responses were also compared between mice receiving a homologous AZD1222 two dose regimen or with a third dose AZD2816 vaccination. A significant increase in total IgG ELISA units was observed against wild-type spike following a booster dose, while a small (albeit not statistically significant) increase against B.1.351 protein was observed (Figure 5B). Antibody binding was observed against all variant spike proteins (Figure 5C), with significantly higher responses observed in AZD2816 boosted mice against variant proteins B.1.1.7 (Alpha) and B.1.429 (Figure 5C). Neutralising responses were detected in all vaccine groups against wild-type spike, B.1.351, B.1.617.1 and B.1.617.2 (Table 1), with higher neutralisation titres against the two variant proteins observed in AZD2816 boosted animals (Figure 5D).

Overall the data shows that a booster dose with a new ChAdOx1 against the new variant B.1.351 (AZD2816), can further enhance antibody responses against SARS-CoV-2 B.1.351 and provide cross-reactivity against other variant proteins.

Discussion:

In populations where vaccination against SARS-CoV-2 has been widely used the impact on prevention of severe disease, hospitalisation and death has been demonstrated, but variant

viruses with mutations in the spike protein are now in circulation, and the efficacy of the original vaccines against VoCs may be reduced.

The VoC B.1.351 was first identified in South Africa and was thought to have driven the second wave of infection resulting in a larger proportion of young individuals being infected than previously seen, with health officials indicating that B.1.351 spreads faster than other variants. B.1.351 contains several mutations across the S1 portion of spike protein. In particular, three mutations involved in binding of spike to the ACE2 receptor have been shown to increase the strength of spike-ACE2 binding, with some antibodies from convalescent or vaccinated individuals showing reduced ability to neutralise this variant virus ⁵. A number of common amino acid changes within the RBD and NTD region of the spike protein have been identified amongst SARS-CoV-2 variants (Table S2). The D614G identified in all VoC, increases virus infectivity ^{7,8}, potentially through increased density of spike on the virion surface ⁹. The L452R change is present in B.1.429, B.1.617.1 and B.1.617.2 shown to reduce sensitivity of neutralising antibodies ⁷. The E484K is present in B.1.351 and P.1 isolates is believed to enhance binding affinity of RBD to ACE2^{10,11} and evasion from antibodies ¹². The N501Y is present in B.1.351, B.1.1.7 and P.1 variants alone does not appear to significantly impact neutralisation, but N501Y in combination with E484K and D614G can affect sera neutralisation titres ^{13,14}. A high proportion of isolated neutralising anti-spike antibody bind to the RBD domain of spike ¹⁵⁻¹⁷, there is concern these cumulative changes are leading to the reduced ability of antibodies induced against WT SARS-CoV-2 to neutralise VoCs 5,18,19

The mRNA and viral vector technologies that allowed rapid production of vaccines against SARS-CoV-2 in early 2020 can be readily employed to express the spike protein from VoCs rather than the original virus. Here we generated AZD2816, a new ChAdOx1 nCoV-19 vaccine expressing B.1.351 spike protein and assessed the immunogenicity in mice. As priming of the immune response to the original wild-type spike protein may impact the ability to switch specificity of the response to B.1.351, we measured antibody and T cell responses after one or two doses of the original ChAdOx1 nCoV-19 vaccine (AZD1222) followed by a single dose of AZD2816.

While a single dose of either AZD1222 or AZD2816 induces rapid T cells and antibodies capable of binding and neutralising wild-type and B.1.351 spike protein, antibody responses can be increased with a booster dose of either AZD1222 or AZD2816. Importantly, we saw no evidence that priming of the immune system response was detrimental when mice received a booster dose of ChAdOx1 expressing B.1.351 expressing protein. Equivalent high levels of T cells were observed, with equivalent cytokines produced and populations of effector and memory T cells (Figure 4). Boosting mice with one dose of AZD2816 after a one or two doses of AZD1222 led to an increase in binding antibody titres in addition to neutralisation against B.1.351 and both B.1.617 variants. In addition, higher antibody titres against P.1, B.1.1.7. B.1.429 and D614G spike was also observed.

Ongoing surveillance has identified B.1.617.2 as a VoC that is spreading rapidly within the UK and elsewhere. Two dose vaccination with AZD1222 induces antibodies capable of neutralising B.1.617.1 and B.1.617.2 (Table 1), and early real-world evidence suggest that the effectiveness of this regimen against hospitalisation and death is maintained

(https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/ file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_England.pdf). Encouragingly neutralisation can be further enhanced with a 3rd dose of vaccine (Table 1), supporting the clinical assessment of these regimens.

The data presented herein demonstrates that vaccination with ChAdOx1 nCoV-19 (AZD1222) induces high titre cross-reactive antibodies capable of neutralising a number of SARS-CoV-2 variants of concern, B.1.351, B.1.617.1 and B.1.617.2. Most importantly these responses can be further enhanced by a booster dose of vaccine expressing the spike protein from B.1.351. These

data support clinical assessment of AZD2816 in vaccine naïve individuals as well as those previously vaccinated with AZD1222.

Methods:

Vector Construction;

AZD2816 vaccine was constructed as previously described ²⁰. In brief, the B.1.351 glycoprotein (S) gene ⁴ was codon-optimized for expression in human cell lines and synthesized with the tissue plasminogen activator (tPA) leader sequence at the 5' end by GeneArt Gene Synthesis (Thermo Fisher Scientific). The S gene was inserted into the Gateway[®] recombination cassette of the shuttle plasmid containing a human cytomegalovirus major immediate early promoter (IE CMV), which includes intron A and two tetracycline operator 2 sites, and the bovine growth hormone polyadenylation signal. BACs containing the ChAdOx1 SARS-CoV-2 B.1.351 Spike protein were prepared by Gateway[®] recombination between the ChAdOx1 destination DNA BAC vector ²¹ and the shuttle plasmids containing the SARS CoV-2 S gene expression cassettes using standard protocols resulting in the insertion of the SARS-CoV-2 expression cassette at the E1 locus. The ChAdOx1 SARS CoV-2 S adenovirus genome was excised from the BAC using unique Pmel sites flanking the adenovirus genome sequence. ChAdOx1 SARS CoV-2 S viral vectors were rescued in T-REx[™] cells (Invitrogen, Cat. R71007), a derivative of HEK293 cells which constitutively express the Tet repressor protein and prevent antigen expression during virus production. The resultant virus, ChAdOx1 nCov-19 B.1.351 (AZD2816), was purified by CsCl gradient ultracentrifugation as described previously. The titres were determined on T-RExTM cells using anti-hexon immunostaining assay based on the QuickTiter™ Adenovirus Titer Immunoassay kit (Cell Biolabs Inc).

Ethics Statement; Mice were used in accordance with the UK Animals (Scientific Procedures) Act 1986 under project license number P9804B4F1 granted by the UK Home Office with approval from the local Animal Welfare and Ethical Review Board (AWERB) at the University of Oxford. Age matched animals were purchased from commercial suppliers as a batch for each experiment and randomly split into groups on arrival at our facility. Animals were group housed in IVCs under SPF conditions, with constant temperature (20-24°C) and humidity (45-65%) with lighting on a 13:11 light-dark cycle (7am to 8pm). For induction of short-term anaesthesia, animals were anaesthetised using vaporised IsoFlo[®]. All animals were humanely sacrificed at the end of each experiment by an approved Schedule 1 method.

Animals and Immunizations; Inbred BALB/cOlaHsd (BALB/c) (Envigo) (n=5 to 7 mice per group), were immunized intramuscularly (i.m.) in the musculus tibialis with 10⁸ infectious units (iu) of ChAdOx1 vector. Mice were boosted with the relevant vaccine candidate 4 weeks later. All mice were sacrificed 3 weeks (or at a time indicated on figure legend) after the final vaccination with serum and spleens collected for analysis of humoral and cell-mediated immunity.

Antigen specific IgG ELISA; MaxiSorp plates (Nunc) were coated with 250ng/well of full-length SARS-CoV-2 wild-type (WT) spike (NC_045512), B.1.351 spike, B.1.1.7 spike, P.1 spike, B.1.429 spike and original wild-type spike sequence with a D to G amino acid substitution at position 614 (D614G) protein (Table S1) overnight at 4 °C, prior to washing in PBS/Tween (0.05% v/v) and blocking with Blocker Casein in PBS (Thermo Fisher Scientific) for 1 hour at room temperature (RT). Standard positive serum (pool of mouse serum with high endpoint titre against original wild-type spike protein), individual mouse serum samples, negative and an internal control (diluted in

casein) were incubated for 2 hrs at RT. Following washing, bound antibodies were detected by addition of a 1 in 5000 dilution of alkaline phosphatase (AP)-conjugated goat anti-mouse IgG (Sigma-Aldrich) for 1 hour at RT and addition of p-Nitrophenyl Phosphate, Disodium Salt substrate (Sigma-Aldrich). An arbitrary number of ELISA units (EU) were assigned to the reference pool and optical density values of each dilution were fitted to a 4-parameter logistic curve using SOFTmax PRO software. ELISA units were calculated for each sample using the optical density values of the standard curve. All data was log-transformed for presentation and statistical analyses.

Micro neutralisation test (mVNT) using lentiviral-based pseudotypes bearing the SARS-CoV-2 Spike; Spike-expressing plasmid constructs were generated using the QuikChange Lightning Multi Site-Directed Mutagenesis kit (Agilent) on a previously described Wuhan-hu-1 template²². Lentiviral-based SARS-CoV-2 pseudotyped viruses were generated in HEK293T cells incubated at 37 °C, 5% CO₂ as previously described ²³. Briefly, cells were seeded at a density of 7.5 x 10⁵ in 6 well dishes, before being transfected with plasmids as follows: 500 ng of SARS-CoV-2 spike (NC 045512, B.1.351, B.1.617.1, B.1.617.2) (Table S1), 600 ng p8.91 (encoding for HIV-1 gag-pol), 600 ng CSFLW (lentivirus backbone expressing a firefly luciferase reporter gene), in Opti-MEM (Gibco) along with 10 μ L PEI (1 μ g/mL) transfection reagent. A 'no glycoprotein' control was also set up using the pcDNA3.1 vector instead of the SARS-CoV-2 Spike expressing plasmid. The following day, the transfection mix was replaced with 3 mL DMEM with 10% FBS (DMEM-10%) and incubated for 48 and 72 hours, after which supernatants containing pseudotyped SARS-CoV-2 (SARS-CoV-2 pps) were harvested, pooled and centrifuged at 1,300 x g for 10 minutes at 4 °C to remove cellular debris. Target HEK293T cells, previously transfected with 500 ng of a human ACE2 expression plasmid (Addgene, Cambridge, MA, USA) were seeded at a density of 2×10^4 in 100 μ L DMEM-10% in a white flat-bottomed 96-well plate one day prior to harvesting SARS-CoV-2 pps. The following day, SARS-CoV-2 pps were titrated 10-fold on target cells, and the remainder stored at -80 °C. For mVNTs, sera was diluted 1 in 20 in serum-free media and 50 µL was added to a 96well plate in triplicate and titrated 2-fold. A fixed titred volume of SARS-CoV-2 pps was added at a dilution equivalent to 10⁵ to 10⁶ signal luciferase units in 50 µL DMEM-10% and incubated with sera for 1 hour at 37 °C, 5% CO2 (giving a final sera dilution of 1 in 40). Target cells expressing human ACE2 were then added at a density of 2 x 10⁴ in 100 µL and incubated at 37 °C, 5% CO2 for 72 hours. Firefly luciferase activity was then measured with BrightGlo luciferase reagent and a Glomax-Multi+ Detection System (Promega, Southampton, UK). Pseudotyped virus neutralisation titres were calculated by interpolating the point at which there was 80% reduction in luciferase activity, relative to untreated controls (80% neutralisation, inhibitory dilution 80, ID80).

ELISpot and ICS staining; Spleen single cell suspension were prepared by passing cells through 70 μ M cell strainers and treatment with ammonium potassium chloride lysis solution prior to resuspension in complete media. Splenocytes were stimulated 15mer peptides (overlapping by 11) spanning the length of SARS-CoV-2 protein and tpa promoter, with peptide pools subdivided into common and variant peptide regions within the S1 and S2 region of spike (Figure 1A) (Table S2). For analysis of IFN γ production by ELISpot, splenocytes were stimulated with two pools of S1 peptides (pools 1 and 2) and two pools of S2 peptides (pools 3 and 4) (final concentration of 2 μ g/mL) on hydrophobic-PVDF ELISpot plates (Merck) coated with 5 μ g/mL anti-mouse IFN γ (AN18). After 18-20 hours of stimulation at 37°C, IFN γ spot forming cells (SFC) were detected by staining membranes with anti-mouse IFN γ biotin (1mg/mL) (R46A2) followed by streptavidin-Alkaline Phosphatase (1mg/mL) and development with AP conjugate substrate kit (BioRad, UK). Spots were enumerated using an AID ELISpot reader and software (AID).

For analysis of intracellular cytokine production, cells were stimulated at 37°C for 6 hours with 2µg/mL a pool of S1 (ELISpot pools 1 and 2) or S2 (ELISpot pools 3 and 4) total original spike peptides (Table S2), media or positive control cell stimulation cocktail (containing PMA-lonomycin, BioLegend), together with 1µg/mL Golgi-plug (BD) and 2µl/mL CD107a-Alexa647 (Clone 1D4B). Following surface staining with CD3-A700 (Clone 17A2, 1 in 100), CD4-BUV496 (Clone GK1.5, 1 in 200), CD8-BUV395 (Clone 53-6.7, 1 in 200), CD11a-PECy7 (Clone H155-78, 1 in 200), CD44-BV780 (Clone IM7, 1 in 100), CD62L-BV711 (Clone MEL-14, 1 in 100), CD69-PECy7 (Clone H1.2F3, 1 in 100), CD103-APCCy7 (Clone 2E7, 1 in 100) and CD127-BV650 (Clone A7R34, 1 in 100) cells were fixed with 4% paraformaldehyde and stained intracellularly with IL2-PerCPCy5.5 (Clone JES6-5H4, 1 in 100), IL4-BV605 (Clone 11B11, 1 in 100), IL10-PE (Clone JES5-16E3, 1 in 100), IFNγ-e450 (Clone XMG1.2, 1 in 100) and TNF α -A488 (Clone MP6-XT22, 1 in 100) diluted in Perm-Wash buffer (BD). Sample acquisition was performed on a Fortessa (BD) and data analyzed in FlowJo V10 (TreeStar). An acquisition threshold was set at a minimum of 5000 events in the live CD3⁺ gate. Antigen specific T cells were identified by gating on LIVE/DEAD negative, size (FSC-A vs SSC), doublet negative (FSC-H vs FSC-A), CD3⁺, CD4⁺ or CD8⁺ cells and each individual cytokine. T cell subsets were gated within the population of "IFN γ^+ or TNF α^+ " responses and are presented after subtraction of the background response detected in the corresponding media stimulated control sample for each mouse, and summing together the response detected to each pool of peptides. T effector (Teff) cells were defined as CD62L^{low} CD127^{low}, T effector memory (Tem) cells defined as CD62L^{low} CD127^{hi} and T central memory (Tcm) cells defined as CD62L^{hi} CD127^{hi} (Figure S1). The total number of cells was calculated by multiplying the frequency of the background corrected population (expressed as a percentage of total lymphocytes) by the total number of lymphocytes counted in each individual spleen sample.

Statistical analysis; All graphs and statistical analysis were performed using Prism v9 (Graphpad). For analysis of vaccination regimen against a single variable (eg IgG level), data was analysed with a one-way anova (Kruskal-Wallis) followed by post-hoc Dunn's multiple comparison test. For analysis of vaccination regimen against multiple variables (eg each individual cytokine or T cell subset) the data was analysed with a two-way analysis of variance, where a significant difference was observed, a post-hoc analysis was performed to compare the overall effect of vaccination regimen. In graphs where a significant difference was observed between multiple vaccine groups, the highest p value is displayed on the graph. All data displayed on a logarithmic scale was log₁₀ transformed prior to statistical analysis (ELISA Units, Neutralisation Titres, Total Cell Numbers).

Data availability; The data that support the findings of this study are available within the article and its Supplementary Information files or are available from the corresponding author upon reasonable request. Source data are provided with this paper.

Acknowledgments; The authors would like to thank the BMS staff for animal husbandry and A. Worth, J.Furze, M. Mykhaylyk and R. Evans for facilities support.

Funding; This research was funded by AstraZeneca. JN, TPP, WSB and DB are funded by the G2P-UK National Virology consortium, MRC/UKRI (grant ref: MR/W005611/1).

Author Contributions; SM, RK, CP cloned and produced virus preparations; AJS, MU, AT, CB & ERA performed animal procedures and/or sample processing; AJS, MU, NT, JN, CB performed

experiments; AJS, NT, DA analyzed data; CL, WD, JM, HD, FRD, DP, TPP, WSB, HB, KR, GS, PM provided reagents; AJS, TL & SG designed the study. AJS & TL wrote the manuscript. All authors reviewed the final version of the manuscript.

Competing interests; SCG is co-founder and board member of Vaccitech and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering the ChAdOx1 nCoV-19 (AZD1222) vaccine. TL is named as an inventor on a patent application covering the ChAdOx1 nCoV-19 (AZD1222) vaccine and was consultant to Vaccitech. PM was an employee of AstraZeneca, KR is an employee of AstraZeneca. HB is an employee of AstraZeneca and is a named inventor on a patent application covering the AZD2816 vaccine.

References:

- 1 Vasileiou, E. *et al.* Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet* **397**, 1646-1657, doi:10.1016/S0140-6736(21)00677-2 (2021).
- Hall, V. J. *et al.* COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet* **397**, 1725-1735, doi:10.1016/S0140-6736(21)00790-X (2021).
- 3 Mahase, E. Covid-19: One dose of vaccine cuts risk of passing on infection by as much as 50%, research shows. *BMJ* **373**, n1112, doi:10.1136/bmj.n1112 (2021).
- 4 Tegally, H. *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.2012.2021.20248640, doi:10.1101/2020.12.21.20248640 (2020).
- 5 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* **184**, 2348-2361 e2346, doi:10.1016/j.cell.2021.02.037 (2021).
- 6 Spencer, A. J. *et al.* Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. *Nature communications* **12**, 2893, doi:10.1038/s41467-021-23173-1 (2021).
- Li, Q. *et al.* The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell* 182, 1284-1294 e1289, doi:10.1016/j.cell.2020.07.012 (2020).
- 8 Hou, Y. J. *et al.* SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* **370**, 1464-1468, doi:10.1126/science.abe8499 (2020).
- 9 Zhang, L. *et al.* SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nature communications* **11**, 6013, doi:10.1038/s41467-020-19808-4 (2020).
- 10 Nelson, G. *et al.* Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. *bioRxiv*, 2021.2001.2013.426558, doi:10.1101/2021.01.13.426558 (2021).
- 11 Wang, W. B. *et al.* E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. *bioRxiv*, 2021.2002.2017.431566, doi:10.1101/2021.02.17.431566 (2021).
- 12 Greaney, A. J. *et al.* Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host Microbe* **29**, 44-57 e49, doi:10.1016/j.chom.2020.11.007 (2021).
- 13 Xie, X. *et al.* Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med* **27**, 620-621, doi:10.1038/s41591-021-01270-4 (2021).
- 14 Li, Q. *et al.* SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. *Cell* **184**, 2362-2371 e2369, doi:10.1016/j.cell.2021.02.042 (2021).
- 15 Zost, S. J. *et al.* Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443-449, doi:10.1038/s41586-020-2548-6 (2020).
- 16 Cerutti, G. *et al.* Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. *Cell Host Microbe* **29**, 819-833 e817, doi:10.1016/j.chom.2021.03.005 (2021).

- 17 Yang, L. *et al.* COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. *Antib Ther* **3**, 205-212, doi:10.1093/abt/tbaa020 (2020).
- 18 Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* **593**, 136-141, doi:10.1038/s41586-021-03412-7 (2021).
- 19 Wibmer, C. K. *et al.* SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat Med* **27**, 622-625, doi:10.1038/s41591-021-01285-x (2021).
- 20 van Doremalen, N. *et al.* ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature* **586**, 578-582, doi:10.1038/s41586-020-2608-y (2020).
- 21 Dicks, M. D. *et al.* A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. *PLoS One* **7**, e40385, doi:10.1371/journal.pone.0040385 (2012).
- 22 McKay, P. F. *et al.* Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nature communications* **11**, 3523, doi:10.1038/s41467-020-17409-9 (2020).
- Graham, S. P. *et al.* Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. *NPJ Vaccines* 5, 69, doi:10.1038/s41541-020-00221-3 (2020).

Prime	Boost	Boost	Time post last vaccine	Original wild-type spike		B.1.351 (Beta)		B.1.617.1 (Kappa)		B.1.617.2 (Delta)	
				ID50	ID80	ID50	ID80	ID50	ID80	ID50	ID80
AZD1222			16 days	186 (70 to 474)	55 (43 to 297)	40	40	40	40	40	40 (40 to 41)
AZD2816			16 days	107 (40 to 297)	40 (40 to 118	81 (51 to 231)	55 (40 to 163)	40 (40 to 42)	40	40	40
AZD1222 & AZD2816			16 days	157 (75 to 248)	65 (40 to 93)	51 (40 to 72)	41 (40 to 51)	40 (40 to 63)	40	40	40
AZD1222	AZD2816		20 days	1285 (541 to 2560)	700 (307 to 1661)	661 (212 to 1719)	235 (167 to 1057)	276 (126 to 964)	177 (85 to 565)	226 (54 to 751)	145 (43 to 467)
AZD1222	AZD1222		48 days	2546 (1789 to 2560)	1158 (627 to 1658)	350 (69 to 630)	111 (51 to 380)	132 (54 to 490)	95 (44 to 185)	40 (40 to 582)	40 (40 to 245)
AZD1222	AZD1222	AZD2816	20 days	2560 (1452 to 2560)	2159 (584 to 2408)	1148 (383 to 2475)	742 (273 to 1628)	724 (397 to 1874)	481 (267 to 947)	637 (87 to 1656)	316 (69 to 1172)

Table 1: Microneutralisation Titres

Functional ability of antibodies to neutralise pseudotyped virus expressing original spike, B.1.351 or B.1.617 spike protein was measured in the serum of vaccinated mice. Pseudotyped virus neutralization titres are expressed as the reciprocal of the serum dilution that inhibited luciferase expression by 50% (ID50) or 80% (ID80). Table shows the median (min to max) per group.




Figure 1: Schematic of SARS-CoV-2 spike protein and peptide pools used in studies

Schematic is a graphical representation of spike protein indicating location of the signal sequence (SS), N-terminal domain (NTD), receptor binding domain (RBD, receptor binding motif (RBM), fusion peptide (FP), heptad repeat (HR) regions, transmembrane domain (TM) and cytoplasmic tail (CT). Peptide pools used to stimulate splenocytes were sub-divided into 4 pools to cover the S1 and S2 regions of spike. Amino acid changes between original and B.1.351 variant virus and encoded in the AZD2816 vaccine construct are indicated.




Figure 2: Immune response following a single dose of ChAdOx1 vaccines


A.) BALB/c mice (n=10) were vaccinated with 10⁸ iu of AZD1222 (ChAdOx1 nCoV-19), AZD2816 (ChAdOx1 nCoV-19 B.1.351) or 10⁸ iu of each vaccine mixed together. Mice were sacrificed 9 or 16 days later to measure antibody and T cell responses.

B.) Total IgG levels measured in the serum of mice against original spike protein (WT) or B.1.351 spike protein.

C.) Microneutralisation titres mVNT (ND50) measured in the serum of mice day 16 post vaccination, against pseudotyped virus expressing original spike (WT) or B.1.351 protein. Limit of detection (LOD) in the assay is defined as a titre of 40.

D.) IFNγ secreting cells measured by ELISpot on day 9 or day 16, with splenocytes stimulated with pools of common peptides, original (WT) spike peptides or corresponding B.1.351 peptides covering the regions of difference between SARS-CoV-2 isolates.

E.) Proportion of IFN γ secreting cells measured against spike common peptides, sub-divided into S1 (pool 1 and pool 2) or S2 (pool 3 or pool 4) regions of spike protein.



Β.




Figure 3: Antibody titres and breadth are increased following a booster dose with AZD2816 vaccine

A.) Graphs show total IgG response against original spike protein (WT) or B.1.351 measured in the serum of mice collected 16 days after vaccination with AZD1222 (n=5) (animals from Figure 2) or a prime-boost regimen of AZD1222 followed 4 weeks later by AZD2816 (n=6).

B.) Graphs show total IgG responses measured against B.1.17, P.1, B.1.429 or D614G spike proteins in serum collected 16 days and 3 weeks after the final vaccination.

All ELISAs were performed simultaneously, data log transformed and analysed with a 2-way anova (repeated measure) with a post-hoc positive test, statistically significant differences between groups (p<0.05) are indicated.

C.) Microneutralisation titre of serum (ND80) collected day 16 post-vaccination (animals Figure 2) and 21 days after prime-boost vaccination against pseudotyped virus expressing original (WT), B.1.351 or B.1.617.1 spike protein. Limit of detection in the assay is defined as a titre of 40 (dotted line). Data was log-transformed and analysed with a 2-way anova (repeated measure) and posthoc positive test, statistically significant differences (p<0.05) between groups are indicated.




Figure 4: T cells responses are boosted by vaccination with variant vaccine AZD2816

A.) BALB/c mice received two doses of 10⁸ iu of AZD1222 (ChAdOx1 nCoV-19) 4 weeks apart and were boosted with 10⁸ iu of AZD2816 (ChAdOx1 nCoV-19 B.1.351) (n=7) or did not receive a final boost (n=5). Mice were sacrificed a further 3 weeks later and splenocytes stimulated with

overlapping SARS-CoV-2 peptides to measure cytokine production by ELISpot or intracellular cytokine staining.

B.) Graphs show IFN γ secreting cells measured by ELISpot with splenocytes stimulated with pools of common peptides, original (WT) spike peptides or corresponding B.1.351 peptides covering the regions of difference between SARS-CoV-2 isolates. Bars graphs represent show the proportion of IFN γ secreting cells measured against spike common peptides, sub-divided into S1 (pool 1 and pool 2) or S2 (pool 3 or pool 4) regions of spike protein.

C.) Graphs show the frequency of cytokine positive CD4⁺ T cells (left), total number of T effector (Tem), T effector memory (Tem) or T central memory cells (Tcm) IFN γ^+ or TNF α^+ CD4⁺ cells (middle), or the proportion of total IFN γ^+ or TNF α^+ CD4⁺ T cells of each T cell subset (right).

D.) Graphs show the frequency of cytokine positive CD8⁺ T cells (left), total number of T effector (Tem), T effector memory (Tem) or T central memory cells (Tcm) IFN γ^+ or TNF α^+ CD8+ cells (middle), or the proportion of total IFN γ^+ or TNF α^+ CD8+ T cells of each T cell subset (right).




Figure 5: Immune response are boosted by immunisation with AZD2816

A.) In the same experiment as described in Figure 4, BALB/c mice received two doses of 10⁸ iu of AZD1222 (ChAdOx1 nCoV-19) 4 weeks apart and were boosted with 10⁸ iu of AZD2816 (ChAdOx1 nCoV-19 B.1.351) (n=7) or did not receive a final boost (n=5). Mice were sacrificed a further 3 weeks later and antibody responses measured in the serum of mice.

B.) Graphs show the total IgG level measured by ELISA against original spike protein (WT) or B.1.351 spike protein. Data was log transformed and analysed with a two-way analysis of variance (repeated measure) and post-hoc positive test, significance between groups (p<0.05) is indicated.

C.) Graphs show total IgG antibody responses measured by ELISA against B.1.1.7, P.1, B.1.429 or D614G spike protein. Data was log transformed and analysed with a two-way analysis of variance (repeated measure) and post-hoc positive test, significance between groups (p<0.05) is indicated.

D.) Graphs show microneutralisation titres mVNT (ND80) measured against pseudotyped virus expressing original (WT), B.1.351, B.1.617.1 or B.1.617.2 spike protein. Limit of detection in the assay is defined as a titre of 40 (dotted line). Data was log transformed and analysed with a two-way analysis of variance (repeated measure) and post-hoc positive test, significance between groups (p<0.05) is indicated.

	Original	B.1.351	B.1.1.7	P.1	B.1.429	D614G	B.1.617.1	B.1.617.2
	Sequence	Beta	Alpha	Gamma	Epsilon		Карра	Delta
	S13				I			
NTD	L18	F		F				
	L19							R
	T20			Ν				
	P26			S				
	H69-V70		Δ					
	D80	А						
	Т95						1	
	D138			Y				
	G142						D	D
	Y144		Δ					
	W152				С			
	E154						К	
	E156-F157							Δ
	R158							G
	R190			S				
	D215	G						
	L242-A243	Δ						
RBD	K417	Ν		Т				
	L452				R		R	R
	T478							К
	E484	К		К			Q	
	N501	Y	Y	Y				
Other	A570		D					
	D614	G	G	G	G	G	G	G
	H655			Y				
	P681		Н				R	R
	A701	V						
	T716		1					
	D950							Ν
	S982		А					
	T1027			I				
	Q1071						Н	
	D1118		Н					
	V1176			F				

Table S1: Sequence changes to SARS-CoV-2 spike protein


Table S2: Overlapping SARS-CoV-2 spike peptide sequences

Pool 1					egion Pool 2					
#	Common Peptides	Original	B.1.351 Sequence	#	Common Peptides	Original	B.1.351 Sequence			
1	MFVFLVLLPLVSSQC	NC_045512 Sequence		7 8		NC_045512 Sequence				
	MFVFLVLLPLVSSQC	LVLLPLVSSQCVNLT	LVLLPLVSSQCVNFT	78	EKGIYQTSNFRVQPT					
2 3		PLVSSQCVNLTTRTQ	PLVSSQCVNFT	80	YQTSNFRVQPTESIV NFRVQPTESIVRFPN					
4		SQCVNLTTRTQLPPA	SQCVNFTTRTQLPPA	81	QPTESIVRFPNITNL					
5		NLTTRTQLPPAYTNS	NFTTRTQLPPAYTNS	82	SIVRFPNITNLCPFG					
6	RTQLPPAYTNSFTRG			83	FPNITNLCPFGEVFN					
/ 8	PPAYTNSFTRGVYYP TNSFTRGVYYPDKVF			84 85	TNLCPFGEVFNATRF PFGEVFNATRFASVY					
9	TRGVYYPDKVFRSSV			86	VFNATRFASVYAWNR					
10	YYPDKVFRSSVLHST			87	TRFASVYAWNRKRIS					
11	KVFRSSVLHSTQDLF			88	SVYAWNRKRISNCVA					
L2 L3	SSVLHSTQDLFLPFF HSTQDLFLPFFSNVT			89 90	WNRKRISNCVADYSV RISNCVADYSVLYNS					
15	DLFLPFFSNVTWFHA			90	CVADYSVLYNSASFS					
15	PFFSNVTWFHAIHVS			92	YSVLYNSASFSTFKC					
L6	NVTWFHAIHVSGTNG			93	YNSASFSTFKCYGVS					
17	FHAIHVSGTNGTKRF			94	SFSTFKCYGVSPTKL					
18 19		HVSGTNGTKRFDNPV TNGTKRFDNPVLPFN	HVSGTNGTKRFANPV	95	FKCYGVSPTKLNDLC GVSPTKLNDLCFTNV					
20		KRFDNPVLPFNDGVY	TNGTKRFANPVLPFN KRFANPVLPFNDGVY	96 97	TKLNDLCFTNVYADS					
21	NPVLPFNDGVYFAST			98	DLCFTNVYADSFVIR					
22	PFNDGVYFASTEKSN			99	TNVYADSFVIRGDEV					
23	GVYFASTEKSNIIRG			100	ADSFVIRGDEVRQIA					
24	ASTEKSNIIRGWIFG			101	VIRGDEVRQIAPGQT	DEVIDOLADOOTOUT				
25 26	KSNIIRGWIFGTTLD IRGWIFGTTLDSKTQ	1		102 103	}	DEVRQIAPGQTGKIA QIAPGQTGKIADYNY	DEVRQIAPGQTGNIA QIAPGQTGNIADYNY			
26	IFGTTLDSKTQSLU			103	1	GQTGKIADYNYKLPD	GQTGNIADYNYKLPD			
28	TLDSKTQSLLIVNNA			104		KIADYNYKLPDDFTG	NIADYNYKLPDDFTG			
9	KTQSLLIVNNATNVV			106	YNYKLPDDFTGCVIA					
0	LLIVNNATNVVIKVC			107	LPDDFTGCVIAWNSN					
1	NNATNVVIKVCEFQF			108	FTGCVIAWNSNNLDS					
2	NVVIKVCEFQFCNDP KVCEFQFCNDPFLGV			109 110	VIAWNSNNLDSKVGG NSNNLDSKVGGNYNY					
4	FQFCNDPFLGVYYHK			111	LDSKVGGNYNYLYRL					
35	NDPFLGVYYHKNNKS			112	VGGNYNYLYRLFRKS					
86	LGVYYHKNNKSWMES			113	YNYLYRLFRKSNLKP					
37	YHKNNKSWMESEFRV			114	YRLFRKSNLKPFERD		-			
88 89	NKSWMESEFRVYSSA MESEFRVYSSANNCT			115 116	RKSNLKPFERDISTE LKPFERDISTEIYQA					
10	FRVYSSANNCTFEYV			117	ERDISTEIYQAGSTP					
11	SSANNCTFEYVSQPF			118	STEIYQAGSTPCNGV					
42	NCTFEYVSQPFLMDL			119		YQAGSTPCNGVEGFN	YQAGSTPCNGVKGFN			
13	EYVSQPFLMDLEGKQ			120		STPCNGVEGFNCYFP	STPCNGVKGFNCYFP			
14 15	QPFLMDLEGKQGNFK MDLEGKQGNFKNLRE			121 122	GFNCYFPLQSYGFQP	NGVEGFNCYFPLQSY	NGVKGFNCYFPLQSY			
+5 16	GKQGNFKNLREFVFK			122	GENCTFFLQSTOPQF	YFPLQSYGFQPTNGV	YFPLQSYGFQPTYGV			
17	NFKNLREFVFKNIDG			124		QSYGFQPTNGVGYQP	QSYGFQPTYGVGYQP			
18	LREFVFKNIDGYFKI			125		FQPTNGVGYQPYRVV	FQPTYGVGYQPYRVV			
19	VFKNIDGYFKIYSKH			126		NGVGYQPYRVVVLSF	YGVGYQPYRVVVLSF			
50	IDGYFKIYSKHTPIN			127	YQPYRVVVLSFELLH					
51 52	+	FKIYSKHTPINLVRD SKHTPINLVRDLPQG	FKIYSKHTPINLVRG SKHTPINLVRGLPQG	128 129	RVVVLSFELLHAPAT LSFELLHAPATVCGP					
53	1	PINLVRDLPQGFSAL	PINLVRGLPQGFSAL	130	LLHAPATVCGPKKST	1				
54		VRDLPQGFSALEPLV	VRGLPQGFSALEPLV	131	PATVCGPKKSTNLVK					
55	PQGFSALEPLVDLPI			132	CGPKKSTNLVKNKCV					
56	SALEPLVDLPIGINI			133	KSTNLVKNKCVNFNF					
57 58	PLVDLPIGINITRFQ	LPIGINITRFQTLLA	LPIGINITRFQTLHR	134 135	LVKNKCVNFNFNGLT KCVNFNFNGLTGTGV					
59 59	1	INITRFQTLLALHRS	INITRFQTLHRSYLT	135	FNFNGLTGTGVLTES					
50		RFQTLLALHRSYLTP	RFQTLHRSYLTPGDS	130	GLTGTGVLTESNKKF					
51		LLALHRSYLTPGDSS	LHRSYLTPGDSSSGW	138	TGVLTESNKKFLPFQ					
52	HRSYLTPGDSSSGWT			139	TESNKKFLPFQQFGR					
53	LTPGDSSSGWTAGAA			140	KKFLPFQQFGRDIAD					
64 65	DSSSGWTAGAAAYYV GWTAGAAAYYVGYLQ	1		141 142	PFQQFGRDIADTTDA FGRDIADTTDAVRDP					
6	GAAAYYVGYLQPRTF	1		142	IADTTDAVRDPQTLE					
7	YYVGYLQPRTFLLKY			144	TDAVRDPQTLEILDI					
8	YLQPRTFLLKYNENG			145	RDPQTLEILDITPCS					
i9	RTFLLKYNENGTITD			146	TLEILDITPCSFGGV					
70	LKYNENGTITDAVDC			147						
71 72	ENGTITDAVDCALDP ITDAVDCALDPLSET			148 149	PCSFGGVSVITPGTN GGVSVITPGTNTSNQ					
72	VDCALDPLSET	1		149	VITPGTNTSNQVAVL					
74	LDPLSETKCTLKSFT			151		GTNTSNQVAVLYQDV	GTNTSNQVAVLYQGV			
75	SETKCTLKSFTVEKG			152		SNQVAVLYQDVNCTE	SNQVAVLYQGVNCTE			
6	CTLKSFTVEKGIYQT			153		AVLYQDVNCTEVPVA	AVLYQGVNCTEVPVA			
7	SFTVEKGIYQTSNFR			154		QDVNCTEVPVAIHAD	QGVNCTEVPVAIHAD			
		1	1	155	CTEVPVAIHADQLTP		1			


International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state International state Internat International state <	
pp AVAY SANGEHAR pp AVAY SANGEHAR pp sp sp< sp< sp< <td></td>	
type ASAQEHAAFRENS Incol Incol STESNATURATINGUE Incol INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING INCOLSTANTING	
Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrume Instrum Instrum Instrume	
Instrume Instrume Instrume Instrume Instrume Image: Instrume Image: Instrume Image: Instrume Image: Instrume Image: Instrume Image: Instrume Image:	
Image Image <th< td=""><td></td></th<>	
Image Image <th< td=""><td></td></th<>	
Image: state in the s	
Image: Image:<	
Instrume Instrume Instrume Peckar Large Peckar Large # Common Peptides Original (C.05512 Sequence) 8.1.315 Sequence # Common Peptides Original (C.0552 Sequence) B.1.315 Sequence B.1	
Screption Pool 4 V Common Peptides Original NC,045512 Sequence I B Common Peptides Original NC,045512 Sequence I D PENAMINES 244 ISV/INDS/INDS/INDS/INDS/INDS/INDS/INDS/INDS	
Unit Unit Designal NC, 05512 Sequence b.1.35 Sequence P. Common Peptides Original NC, 05512 Sequence B. 188 GICAXYGTQTNSPRR Image and the sequence 242 USANRCASSYUNDUS Image and the sequence 1 199 STOTOTINSPRARASY Image and the sequence 243 USANRCASSYUNDUS Image and the sequence 1 190 GTUSTRARASYASY Image and the sequence 244 USANRCASSYUNDUS Image and the sequence 1 171 PREARSYASQSIAV SQSIAVITMSL CALVEN 246 USANRCASSUNDUS Image and the sequence 1 172 RXXASQSIAVITMSL SQSIAVITMSL CALVEN 248 USANRCASSUNDUS 1 1 173 MASGARSYANTMAS MASGARSYANTMAS MASGARSYANTMAS 240 USANRCASSUNDUS 1<	
a Common Peptides Original NC_05521 Sequence (CASY010TNSPRR A) B.1.351 Sequence AC_055176AISSVIND B. Common Peptides NC_05521 Sequence AC_055176AISSVIND B. 188 SUCTOTNSPRR ASVASOS 243 NCGASY10AISSRR ASV (CASSY2051477 244 ISVINDISULVENT 1 171 RPRASEXSSIAVT 245 ISVINDISULVENT 2 ISVINDISULVENT 1 172 RSVADSSASSIAVT SQSIIAVTMSLOCEN 246 ISVINDISULVENT 1 1 173 ISVINDISULVENT 246 ISVINDISULVENT 246 ISVINDISULVENT 1 174 ISVINDISULVENT 147 ISVINDISULVENT 248 ISVINDISULVENT 1 175 MISINITYT ALINSAVESINSIAN 1251 ISVINDISULVENT 1 1 178 INSIAIPENTITYTE 1 2321 GUINAGIOSANAN 1 1 178 INSIAIPENTITYTE 1 2323 GUINAGIOSANAN 1 1 178 INSIAIPENTITYTE 1 2334 INSIAIPENTITYTE 1 1 </td <td></td>	
n Common Prepriete NC_045512 Sequence N 188 GICATOTINSPRR COMSON Prepriete Common Prepriete Common Prepriete 199 SYGTCTINSPRRARASYO COMSON Prepriete COMSON Prepriete Common Prepriete 190 GIVESPRRARASYOS COMSON Prepriete COMSON Prepriete Common Prepriete 191 PREARSYARSS SOBIATYTISLOW 246 LADIALDOVACY Common Prepriete 171 PREARSYARSS SOBIATYTISLOW 246 LADIALDOVACY Common Prepriete Common Prepriete 173 SOSIATYTISLOW LATMISGOENSVA 248 LADIALDOVACY Common Prepriete Common Preprise Common Preprise </td <td></td>	
NC_00512 Sequence NC_00512 Sequence 109 STQTOTNSHRANKSV 242 CLSSNFGARSVLNDLGR 1 109 STQTOTNSHRANKSV 244 SVENUDISLAS 1 101 TISSNFGARSVLDS 244 SVENUDISLASVLDS 1 111 PRARSVLSQSIAV 245 LINDISRIDVERVU 1 121 RVASSIATTMSL SQSIATTMSLOVEN 246 LINDISRIDVERVUD 1 122 RVASSIATTMSL SQSIATTMSLOVEN 244 LINDISRIDVERVUD 1 122 RVASSIATTMSL SQSIATTMSLOVENVA 244 LINDISRIDVERVUD 1 123 NUSIANTMEL SQSIATTMSLOVENVA 244 LINDISRIDVERQ 1 124 LINDISRIDVERQ 1 LINDISRIDVERQ 1 1 125 RINSIANTMEL 212 LINDISRIDUC 1 <t< td=""><td>B.1.351 Sequence</td></t<>	B.1.351 Sequence
190 SYGTGYNSPRAASY P 243 NFGASSVADUIGS P 170 OPRSARVAGGS P 244 DSVANDUSLOVA P 171 PRAASVAGGS P 246 LADUSALDOVAEV P 173 PRAASVAGGS SGUANTYMSLOARN 246 LSUNDUSAVUQUDR P 173 SCANATYMSLOARN SGUANTYMSLOARN 247 DAVLATAUQUDR P 174 LANDUSALDANS MSLGANSVATSMS MSLGANSVATSMS 248 DAVLATAUQUDR P 175 MSLGANSVATSMSA MSLGANSVATSMSA 249 LORALGYATYOQU P 176 ANSVATSMSAR PVENSVATSMSAR 290 LORALGYATYOQU P 178 MSLGANSVATSMSAR PVENSVATSMSAR 291 LORALGYATYOQU P 179 APRINTSTYTT P 273 TAQUIRALITAKAN P P 181 SVTEUSTATINST P 275 LAALITAKANAN P P P P P P P P P P <td>B.1.351 Sequence</td>	B.1.351 Sequence
101 OTHSPRARSYASS PARA SYS PARA SYS 121 PRASSSSINT PARA SYS PARA SYS 122 RSVASSSINT PARA SYS PARA SYS 123 RSVASSSINT SSSINT/MSL SIC PARA SYS 124 RSVASSINT/MSL SIC SSSINT/MSL SIC PARA SYS 125 PARA SYS SSSINT/MSL SIC PARA SYS 126 PARA SYS ANT/MSL SIC PARA SYS 127 VASSINSAIPT PARA SYS SSSINT/MSL SIC PARA SYS 128 NUSIAPTINTIST PARA SYS PARA SYS PARA SYS PARA SYS 129 APTINTISTIT PARA SYS PARA SYS <t< td=""><td></td></t<>	
11 PRAMES/ASGENTY Inc. 245 INDERGRUARY Inc. Inc. 121 RSXADSIATTASL SCOIMATTASL SCOIMATTASL INC.	
12 BSVAGSDMATTMSL Common Sector 246 SUBJOYAGEAGEN 247 SUBJOYAGEAGEN 247 SUBJOYAGEAGEN 247 SUBJOYAGEAGEN 248 ALVOIDRUTGRUGS 141 174 IAVTIMS GARMAYAYAN MASKUPYANSYANS 248 ALVOIDRUTGRUGS 141 175 IAVTMS GARMAYAYANSYANS 249 INELDSONT 141 176 ALENSALTSANSIALP 250 ITERUS (DYTVIDUR 141 177 VAYSINSALPTITI IAUTANS (ANYANSYANSYANS) 240 IDUIDALALALALAL 141 178 INISKUPIPTITIL IAUTANSALTSANSANSANS IDUIDALALALALALALALALALALALALALALALALALALAL	
173 SCRIMTYMSGARNY 250 VTRASCARNYNY 247 DVRARVGRUNTGR MACH 174 MASGARNYATNIS MASGARNYATNIS MASGARNYATNIS MACH MACH MACH 175 MASGARNYATNIS MASGARNYATNIS MASGARNYATNIS MASGARNYATNIS MASGARNYATNIS MACH MACH <td< td=""><td></td></td<>	
174 INTIMISAGENSIVI INTIMISAGENSIVI 248 AEVQIDEUTIGNUS 175 MISGARIVAVISMIS MISCARIVAVISNISMIS 249 IDEUTIGNUS []] 176 AENSIVATSINISMIP 250 IDEUTIGNUS []] <td></td>	
Instruction MSLGKENSVAYSINS 249 IDRUTGRUGQUYTCQ Personance 176 KARSVAYSINSLAP VENSVAYSINSLAP 250 ITGRUGQUYTCQ Personance 177 VAYSINSAPTINT Personance 251 IDSLICTVTCQUBAAEIR Personance 178 NISAPTINTT Personance 253 ITGUTAAEIRAAN Personance 180 NITSUTTELPXM Personance 253 ITGUTAAEIRAAN Personance 181 SVTELINVSMIKTS Personance 255 EIASANLATIKISSUCCT Personance 182 ELPYSMIKTSVOCTM Personance 256 SANLATIKISSUCGSGR Personance 183 VSMIKTSVOCTM Personance 259 VIGQSMIVECGSGR Personance 184 KTSVOCTMVCGDSTCS Personance 260 SKRVDFCGKYL Personance Personance 185 DETSCMILQUCSFTCIA Personance 261 DETSCMIVECGKYL Personance Personance Personance Personance Personance Personance Personance Personance Personance	
176 AENSYAYSINSIAIP VENSYAYSINSIAIP 230 ITGRUGS.QTYYTQQ. () 177 VAYSINSIAPTINT 251 IQSI.QTYYTQQ.IIBAAEIR) 178 NINSIAPTINTTSVT 252 QTYVTQQ.IIBAAEIR) 179 APTINTTSVTELL 1 253 ITQQ.IIAAEIRASANAAT 181 SYTTELIPSVMTKTS 1 255 EIRASANLAATINSEC) 181 SYTTELIPSVMTKTSVDCT 255 EIRASANLAATINSEC)) 183 VSMTKTSVDCTMIC 253 MSCVG.QGSKRVFC) <td></td>	
177 VAYSINDAPITNIT [214] [203:GTVTGQUBAAER [215] 178 NISAIPITNITUT [225] GTVTGQUBAAER [216] 179 AIPINTTSUTTEL [236] IRAGERSANLART [216] 180 NFTSVTEUPUSM [256] IRAGERSANLART [216] 181 SUTEUPUSMITIS [256] ISANLARTMSEC [216] 182 ELPSMITISVDCTMIC [257] ARTMSECKIGGSR [216] 183 VSMITSVDCTMIC [258] ISANLARTMSECKIGGSR [216] 184 KTSVDCTMICGSTSTS [259] VIGGSRWOPCCKCY [216] 185 DTCMICGSTCSNILQ [260] DFCGKPHIMSPQ3 [216] 186 VIGGSTCTUMAL [261] DFCGKPHIMSPQ3 [216] 188 LQUXGSFCTULRAL [262] MSWIMSPQAMHOVEL [216] 190 GSFCTQUNRALTGIA [264] MSWIMSPQAMHOVEL [216] 191 TUBARTGAVCOD [266] VILINTVPAQENTHAL [216] 192 BALTGANCOLONNTO [266] VILINTVPAQENTHAL [216] 193 GALVEQOKGRYMM [266]<	
19 APTINTENTELL 233 TQQUBARERSANT 241 190 NETSYTTELPYSM 254 BRARERSANLAAT 1 181 STTELPYSMIKTS 255 EIRASANLAATKMSE 1 182 ELPASMIKTSVOCTM 256 SANLAATKMSECVLGG 1 183 VSMIKTSVOCTMVC 256 SANLAATKMSECVLGGSKR 1 184 KTSVOCTMVCGOST 258 MSECVLGGSKRVDFCGKOF 1 184 KTSVOCTMVCGOSTS 260 SKRVDFCGKOPL 1 185 DCTMVCGSTECSN 261 DTCKCKYHLMSPOG 1 186 LQYGSFCTQL NRAL 261 DTCKCKYHLMSPOG 1 187 DGLSKULQYGSF CTQL 262 KGYHLMSPOGAPHG 1 188 LQYGSFCTQLNRAL 261 DTCKCKYHLMSPOG 1 189 LQYGSFCTQLNRAL 263 LMSPQSAPHGVYEL 1 191 TQURAKUQKKQQ 265 PHGVVFLVYVRAQ 1 192 RALTGAVEQDKYTQ 266 VTLVYVRAQEKNTTAPALCH 1	
180 NTTSUTTELPSYM 254 IFAREIRASANLAATKMAT 0 181 SYTTELPSYMITKTS 255 EIRASANLAATKMASE 1 182 ELPSYMITKTSVDCT 256 SANLAATKMASE 1 183 VSMITKTSVDCTMVC 257 AATKMEECUEGOSKR 1 184 KTSVDCTMVCGOST 258 MSECUEGOSKRVDC 1 185 DCTMVICCOSTECSIN 259 VLGOSKRVDCGKOV 1 186 SCHUCGOSTECSIN 261 DFCGKOVHLMSVPGKOV 1 187 DSTECSNILLQ 262 KGYHLMSVPGCKOVHLM 1 188 CSNILLQYGSFCIQL 263 LMSYFQSAPHGVHL 1 189 LQUGSCIQLINAAL 263 LMSYFQSAPHGVHL 1 190 GSKTCIQLINAAL 264 PQSAPHGVHLHVTVPAQ 1 191 TQURANTGAVEAQ 265 PHGVUVHLWTVPAQ 1 192 RALTGIAVEQOKNTQ 269 KNPTTAPAICHORGA 1 193 IAVERPAICHONQUQ 284 PAQEKWFTAPAICH 1	
181 SYTTELPYSMITKYS 255 EIRASANLARTKSE 251 182 EUPSKITSYDCT 256 SANLARTKSECVLGQSKR 1 183 VSMTKTSVDCTMVIC 257 AATKMSECVLGQSKR 1 184 KTSVDCTMVICGDST 258 MECVLGQSKROPC 1 184 KTSVDCTMVICGDSTESN 259 VIGGSKROPCGKOP 1 185 DCTMVICGOSTESN 260 SKROVDCGKOPC 1 186 VIGDSTECSNLLQQ 261 DECKCKYHLMSPPQS 1 188 LQVGSTCUINAL 262 KGYLLMSPGSAPHGVFL 1 190 GSECTQLINAL 264 PQSAPHGVFL 1 191 TQLMGALQGKNTQ 265 PHGVVFLMTYPL 1 193 GAVEGQKNTQEVFA 267 VTVPAQEKNTTAP 1 194 EQNKTQVKQQ 268 PAGKWFTAPK 1 195 NTGLVFAQXKQWKT 269 KKNTTAPAICHOKA 1 194 EQNKTQVKTYKT 270 TAPAICHOKA 1 195	
122 ELUPYSMITKTSVDCT Image: Constant of the second	
133 VSMTGYDCTMVC 257 ARXMSECUGQSR 258 184 KTSVDCTMVICGDST 258 MSECVLGQSRR/DEC 1 185 DCTMVICGDSTECSN 250 VIGQSRR/DEC/GKCY 1 186 YICGDSTECSNLLQ 260 SKRVDEC/GKCY 1 187 DSTECSNLLQYCSF 261 DFCGKGVHIMSFDS 1 188 CSNLLQYCSF CTQL 263 IMSFDQSAPHG/VFL 1 199 LQYGSTCQLNRAL 263 IMSFDQSAPHG/VFL 1 191 TQLNRALTG/MVCD 265 PHGVVFL/VTVPAQ 1 193 GAVEQDKNTQVFA 265 PHGVVFL/VTVPAQ 1 194 EQKKINGVEQDK 265 PHGVVFL/VTVPAQ 1 195 RALGAVEQDKNTQ 266 VFL/VTVPAQEKMF 1 193 GIAVEQDKNTQVFA 267 VTVVPAQEKMF 1 194 EQKKINGVEXMARQ 268 KARKAVERMF 1 195 NTQEVFAQVKQIYKT 270 TAPAICHOGKAHFR 1 196	
134 KTSYDETMYEGDST [25] MSECUGOST [25] VIGOSKRVDECGKGY [26] 135 DETMYEGDSTEGSN [26] SKRVDECGKGY [26] 137 DSTECSNILLQ [26] SKRVDECGKGYH [26] 138 CSNILLQYGSF [26] DECGKGYHIMSPAGS [26] 138 CSNILLQYGSFTCI [26] MSFPGSAPH6 [26] 139 LQYGSFCTQLINAL [26] MSFPGSAPH60VFL [26] 130 GSFCCDINRALTGA [26] PGSYPCHOVFL [26] 131 TQLINRALTGA [26] PGSYPCHOVFL [26] 132 RALGAVEQD [26] VFLWTYPAQEKNFTAP [26] 133 GIAVEQDKNTQ [26] [27] [26] 134 EQDNTGEVFAQVAQYK [26] [27] [27] 135 NTGEVFAQVAQYK [26] [27] [27] [26] 136 VFAQWAGYKTPREVERGE [27] [27] [27] [27] [27] [27] [27] [27]	
185 DCTMVIG0STECSN 259 VLGQSKPVEGKGY 1 186 VIGDSTECSNILLQ 260 SKRVDFCGKGYHLMS 1 187 DSTECSNILLQVGSF 261 DFCGKGYHLMS 1 188 CSNILLQVGSF 262 KGYHLMSPQ3APHG 1 188 CSNILLQVGSF 263 KGYHLMSPQ3APHG 1 190 GSKTGLNRAL 263 KGYHLMSPQ3APHGVVFL 1 191 TQLNRALTGIAVEQD 265 PHGVVFLHYTVPAQ 1 192 RALTGIAVEQDKVTQ 266 VFLHYTVPAQENFT 1 193 GGAVEQDKNTQUFVFA 266 NEHTTYVPAQ 1 194 EQDKTYCEVFAQVKQ 268 RNETTAARLCH 1 195 VFAQVKQIWKT 270 TAPAICHDGKA 1 196 VFAQVKQIWKT 271 ICHDGKAHFPR 1 197 VKQINTPIKOFGG 271 ICHDGKAHFPRE 1 198 VKTPKNEOFGENSCILP 273 ISKHTHAFCOFF 1 199 PKDSCFONSC	
186 VICGDSTECSNILLQ 260 SKRUPCRGWHMS 261 187 DSTECSNILLQVGSF 261 DFCGKGYHLMSFPQSAHG 261 188 CSNILLQVGSFCTQL 263 LMSFPQSAHGVFL 261 199 LLQVGSFCTQLNRAL 263 LMSFPQSAHGVFL 261 190 GSFCTQLNRALTGIA 264 PQSAPHGVVFLHVTVVPAQ 261 191 TQLINRALTGIAVEQD 265 PHGVVFLHVTVPAQ 261 192 RAITGIAVEQDKNTQCVFA 266 VFLHVTVPAQENNTPA 261 193 GIAVEQDKNTQCVFA 266 PAQEKNTAPALCH 261 194 EQDKNTQEVFAQVKQWT 268 PAQEKNTAPALCH 261 195 NTCEXPAQVKQWT 270 TAPAICHDGKAHFPR 271 197 VKQMKTPPIK 272 GAHPRECVFVSNG 272 198 YETPKDFGGFNS 272 GAHPRECVFVSNG 272 199 FKDFGGFNSSQLP 273 FPRECVFVSNG 274 201 NSQLIPDPSKFSKR 275 GAVFVSNGTHWFVTQR 274	
187 DSTECSNILLQYGSF 261 DFCGKOYHLMSFPQS 1 188 CSNILLQYGSFTQL 262 KGYHLMSFPQSAPHG 1 189 LQYGSFTQLNRAL 263 KGYHLMSFPQSAPHG 1 190 GSSCTQLNRALTGIA 264 PQSAPHGVVFL 1 191 TQLINRALTGIAVEQD 265 PHGVVFLMTTVVPAQ 1 192 RALTGIAVEQDKNTQ 266 VTUYPAQENNTTA 1 193 GGAVEQDKNTQEVFAQ 268 NETAGNALCHOKAN 1 194 EQDKINTQEVFAQVKQ 268 NETAGNALCHOKAN 1 195 NTQEVFAQVKQUKT 270 TAPAICHOKAN 1 196 VFAQUKQINKTPIK 271 TAPAICHOKAN 1 197 VKQWATPPIKK 272 TAPAICHOKAN 1 198 PKNFDKOFGGFNFS 271 ICHOKAFFPR 1 201 NFGQENFSQLPP 273 FOREGVFVSNGF 1 201 NFGVERSKSR 274 GVFVSNGTHWF 1 202 IEGFM	
188 CSNLLQYGSFCTQL IM 262 KGMMUSPQSAPHG IM 189 LQYGSFCTQLINALTGIA 263 LIMSFPQSAPHGVVFL IM 189 LQYGSFCTQLINALTGIA 264 PQSAPHGVVFL IM 191 TQLINALTGIAVEQD 265 PHGVVFLWTYVPAQ IM 193 GIAVEQDKINTQE 265 PHGVVFLWTYVPAQ IM 193 GIAVEQDKINTQEVFA 266 PAGKMFTTAPAICH IM 194 EQDKINTQEVFAQVKQVKT 268 PAQKMFTTAPAICH IM 195 NTQEVFAQVKQVKT 268 PAQKMKDKTBGKA IM 196 VFAQVKQVKTPHK 270 TAPAICHOGKAHFPREGVF IM 197 VKQWKTPHKDEGG 271 ICHDGKAHFPREGVF IM 198 YKTPHKDFGGFNS 2721 GKAHFPREGVFSMG IM 201 INSQLPSPSKSR 2724 GVFVSNGTMWFVTQR IM 202 ILPDSKSPSKSSR 273 SPREGVFSNGTMWFVTQR IM 203 SKRSFRSHEDLLF 275 SNGTMVFVTQRNYFQI	
189 LLQYGSFCTQLINRAL IMS 263 LMSYEQSAPHGVVFL IMS 190 CSFCTQLINRALTGIAC 264 PQSAPHGVVFLVTY IMS 191 TQLINRALTGIAVEQD 265 PHGVVFLIVTYPAQ IMS 192 RALTGIAVEQDKNTQ 266 VFLIVTVPAQEKNF IMS 193 GIAVEQDKNTQVKQ 266 VFLIVTVPAQEKNFTAPA IMS 194 EQDKNTGEVFAQKQ 266 VFLIVTVPAQEKNFTAPA IMS 195 NTQEVFAQKQNKTFK 269 KNFTPAQICHOGKAHFRA IMS 195 VFAQVKQNKTFNK 270 TAPALCHOGKAHFRA IMS 196 VFAQVKQNKTFNK 271 ICHDGKAHFRGVFVSMG ICHDGKAHFRGVFVSMG 197 VKQIYKTPNIKDFGG 272 GKAHFRGGVFVSMG IMS 200 FGGFNFSQLIPPSK 272 SNGTHWFTQRNFTQ IMS 201 NFSQILPPSKSR 275 SNGTHWFTQRNFTQ IMS 201 NFSQILPPSKSKSFIE 276 SNGTHWFTQRNFTQ IMS 203 FREDLIFNKUT 277	
190 GSFCTQLINRALTGIA Image: Constraint of the second seco	
191 TQLINRALTGAVEQD 265 PHGVVFLHVTVYPAQ 1 192 RALTGAVEQDKNTQ 266 VFLHVTVYPAQEKNFF 1 193 GAVEQDKNTQEVFA 267 VTVVPAQEKNFF 1 194 EODKNTGEVFAQVKQ 268 PAQEKNFTAPAICH 1 195 NTQEVFAQVKQVKT 269 KNFTTAPAICHOGKA 1 195 NTQEVFAQVKQVKT 270 TAPAICHOGKA 1 196 VFAQVKQVKTPRIK 270 TAPAICHOGKA 1 197 VKQVKTPRIDDGGFNFS 271 ICHOCKAHFPREOVF 1 198 YKTPRIDDFGGFNFS 272 GKAHFPREOVFVSNG 1 1 200 FGGFNFSQLIPPSK 274 GVPSNOTHWFVTQR 1 1 201 NFSQLIPPSKPSKR 275 SNOTHWFVTQRNFVEQUINT 1 1 203 PSKPSKRSFIEL 277 TQRNFYEQUINTOR 1 2 204 SKRSFEDLIFKNT 278 FVFPQUITTON 1 2 205 FREDLIFNKTIADA <td< td=""><td></td></td<>	
193 GIAVEQDKNTQEVFA 267 VTVVPAQEKNFTTAPA 194 EQDKNTQEVFAQVKQ 268 PAQEKNFTTAPALCH 195 NTQEVFAQVKQIWKT 269 KNFTTAPALCH 196 VFAQVKQIVKTPIK 270 TAPAICHDGKA 1 197 VKQIVKTPRIKDFGG 270 TAPAICHDGKA 1 198 VKTPRIKDFGGFNFS 271 GKAHFPREGVFVSNG 1 200 FGGFNFSQILP 273 FPREGVFVSNGFHWF 1 201 NFSQLPDPSKSKR 274 GKVVSNGTHWFTQR 1 201 NFSQLPDPSKPSKR 275 SNGTHWFTQR 1 202 ILPDPSKPSKRSFIE 276 HWFVTQRNFYEQUITDN 1 203 PSKSKRSFIELLF 277 TQRNFVEPQUITDN 1 204 SKRSFEDLIFNVT 278 FYEPQUITTDNTFVS 1 205 FIEDLIFNVTLADA 279 QUITDNTFVSGNCD 1 206 LIFNKVTLADA 280 TDNTFVSGNCDVIG 1 207 KVTLADAGFIKQYGD 281	
194 EQDKNTQEVFAQVKQ 268 PAQEKNFTTAPAICH 195 NTQEVFAQVKQVKT 269 KNFTTAPAICHDGKA 1 195 VFAQVKQVKQVKT 270 TAPAICHDGKAFPR 1 197 VKQIYKTPPIK 270 TAPAICHDGKAFPR 1 197 VKQIYKTPPIK 271 ICHDGKAHFPREGVF 1 198 YKTPPIKDFGG 271 ICHDGKAHFPREGVF 1 199 PIKDFGGFNFSQILP 273 FRREGVFVSNGTHWF 1 200 FGGFNFSQILPDPSK 274 GVFVSNGTHWFVQR 1 201 NFSQLIPDPSKPSKR 275 SNGTHWFVTQRNFYEQUI 1 202 ILIPDSKPSKRSFIE 277 TQRNFYEQUITDN 1 203 PSKPSKRSFIEL 277 TQRNFYEQUITDN 1 204 SKRSFIEDLIF 277 TQRNFYEQUITDN 1 205 FIEDLIFNKVTLADA 278 QUITDNTFVSGNCD 1 206 LLFNKVTLADAGFIK 280 TDNTFVSGNCDVIG 1 207 KVTLADAGFIKQYGD<	
195 NTQEVFAQVKQIYKT 269 KNFTTAPAICHDGKA 196 VFAQVKQIYKTPIK 270 TAPAICHDGKAHFPR 1 197 VKQIYKTPIKDFGG 271 ICHOGKAHFPREOVF 1 198 YKTPIKDFGGFNFS 272 GKAHFPREOVFSNG 1 199 PIKDFGGFNFSQLIP 273 FPREGVFVSNGTHWF 1 200 FGGFNFSQLIPDSK 273 SNGTHWFVTQR 1 201 NFSQLIPDPSKSRR 275 SNGTHWFVTQRFYE 1 202 ILPDPSKPSKRSFIE 276 HWFVTQRNFYEQII 1 203 PSKPSKRSFIEDLIF 277 TQRNFYEPQIITDN 1 204 SKRSFIEDLIFKVT 278 FYEPQUITDNTFVS 1 205 FIEDLIFNKVTLADA 279 QIITTDNTFVSGNCD 1 206 LIFNKVTLADAGFIK 280 TDNTFVSGNCDVIGIVN 1 208 ADAGFIKQYGDCLGD 281 FVSCNCDVVGIVNN 1 209 FIKQYCDCLGDAAR 283 VIGVNNTVYDLPC 1 210	
196 VFAQVKQIYKTPPIK 270 TAPAICHDGKAHFPR 197 VKQIYKTPPIKDFGG 271 ICHOGKAHFPREGVF 198 YKTPPIKDFGGFNFS 272 GKAHFPREGVF/SNG 199 PIKDFGGFNFSQILP 273 FPREGVF/SNGTHWF 1 200 FGGFNFSQILPDPSK 274 GVF/SNGTHWFVTQR 1 201 NFSQILPDPSK 274 GVF/SNGTHWFVTQR 1 201 NFSQILPDPSK 276 HWFVTQRNFYEQII 1 202 ILPDPSKPSKRSFIE 276 HWFVTQRNFYEQII 1 203 PSKPSKRSFIEDLLF 277 TQRNFYEQIITDN 1 204 SKRSFIEDLLFKVT 278 FVEPQIITTONTVS 1 205 FIEDLFNKVTLADA 270 INTONTFVSGNCD 1 206 LIFNKVTLADAGFIK 280 TDNTFVSGNCD 1 207 KVTLADAGFIKQYGD 281 FVSGNCDVVIG 1 208 KAQVGQCLGD 283 VIGVIGVINNTVPD 2 209 FIKQYGDCLGDLAAR 283	
197 VKQIYKTPPIKDFGG 271 ICHDGKAHFPREGVF 198 YKTPPIKDFGGFNFS 272 GKAHFPREGVFVSNG 199 PIKDFGGFNFSQILP 273 FPREGVFVSNGTHWF 200 FGGFNFSQILPDPSK 274 GVFVSNGTHWFTQR 201 NFSQILPDPSK 275 SNGTHWFVTQRNFYE 202 ILPDPSKPSKRSFE 276 HWFVTQRNFYE 203 PSFSSKSFEDLIF 277 TQRNFYEQIIITDN 204 SKRSFIEDLIFNKVT 278 FYEPQIITTDN 205 FIEDLFNKVTLADA 279 QIITTONTFVSGNCD 206 LIFNKVTLADAGFIK 280 TDNTFVSGNCD 207 KVTLADAGFIKQYGD 281 FVSGNCDVVIGINN 208 ADAGFIKQYGDLGD 282 NCDVVIGINNNVDPLQP 209 FIKQYGDCLGDIAAR 283 VIGVNNTVVDPLQP 210 YGDCLGDIAARDILC 284 VNDVVDPLQPELDS 211 LGDIAABULCAQKF 285 VVDPLQPELDSFKEE 213 LGQKKNGLTVLPP 287 LDSFKEELDKYKNH 214 <t< td=""><td></td></t<>	
198 YKTPPIKDFGGFNFS 272 GKAHFPREGVFVSNG 1 199 PIKDFGGFNFSQLUP 273 FPREGVFVSNGTHWF 1 200 FGGFNFSQLUPDPSK 274 GVFVSNGTHWFVTQR 1 201 NFSQLIPDPSKR 275 SNGTHWFVTQRNFYE 1 202 ILPDPSKPSKR 275 SNGTHWFVTQRNFYE 1 203 PSKPSKBFIEDLLF 276 HWFVTQRNFYEQUII 1 204 SKRSFIEDLLFNKVT 277 TQRNFYEPQUITDN 1 204 SKRSFIEDLLFNKVT 278 FYEPQUITTDN 1 205 FIEDLFNKVTADAG 279 QUITDNTFVSONCD 1 206 LUFNKVTADAGFIK 280 TDNTFVSONCD 1 207 KVTLADAGFIKQGD 281 FVSGNCDVVIG 1 208 ADAGFIKQYGDCLGD 282 VGDVVNNVTVPLQP 1 209 FIKQYGDLGDIAAR 283 VIGIVNNTVYDLQPLQP 1 210 YGDCLGDIAARDUC 284 VNTVTVDLQPLQPELDS 1 211	
199 PIKDFGGFNFSQILP 273 FPREGVFVSNGTHWF 2 200 FGGFNFSQILPPSK 274 GVFVSNGTHWFVTQR 2 201 NFSQILPDPSKPSKR 275 SNGTHWFVTQRNFYE 2 202 ILPDPSKPSKRSFIE 276 HWFVTQRNFYEQII 2 203 PSKPSKRSFIEDLLF 277 TQRNFYEPQIITTDN 2 204 SKRSFIEDLLFNVT 278 FYEPQIITTDNTFVS 2 205 FIEDLLFNKVT 279 QIITTDNTFVSGNCDVVIG 2 206 LENKVTLADAGFIK 280 TDNTFVSGNCDVVIG 2 207 KVTLADAGFIKQYGD 281 FVSGNCDVVIGIVNN 2 208 ADAGFIKQYGDCLGD 282 NCDVVIGIVNNTVD 2 209 FIKQYGDCLGDIAAR 283 VGIVNNTVPDLQP 2 210 YGDCLGDIAAR 283 VGIVNNTVPDLQP 2 211 LGDIAARDLIC 284 VNNTVVDLQPELDS 2 212 AARDLICAQKF 285 VUPLQPELDSFKEE 2 21	
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	
203PSKPSKRSFIEDLLF277TQRNFYEPQIITTDN204SKRSFIEDLLFNKVT278FYEPQIITTDNTFVS205FIEDLLFNKVTLADA279QIITTDNTFVSGNCD206LLFNKVTLADAGFIK280TDNTFVSGNCDVIG207KVTLADAGFIKQYGD281FVSGNCDVVIGVNN208ADAGFIKQYGDLGD282NCDVVIGIVNNVYD209FIKQYGDCLGDIAAR283VIGIVNNTVYDPLQP210YSDCLGDIAARDLIC284VNNTVYDPLQPELDS211LGDIAARDLICAQKF285VYDPLQPELDSFKEE212AADLICAQKFNGIT286LQPELDSFKEE213LICAQKFNGIT286LQPELDSFKEELDKY214QKFNGLTVLPPL287LDSFKEELDKY215GLTVLPPLITD288KEELDKYFKNH216LPPLITDEMIA289DKYFKNHTSPDVDLG217ITDEMIAQYTSALLA290KNHTSPDVDLGDISG218MIAQYTSALLAGTIT292DLGDISGINASVVNI219YTSALLAGTITSGWT293ISGINASVVNIQKEI210LAGTITSGWTFGAG294NASVVNIQKEIDRLN221TITGWTFGAAALQ295VNIQKEIDRLN222GAGAALQIPFA295VNIQKEIDRLN224ALQIFFAMQMA297RLNEVAKNLNESLID224ALQIFFAMQMAYRFN298VAKNLNESLIDQEL	
205FIEDLLFNKVTLADA279QITTDNTFVSGNCD1206LLFNKVTLADAGFIK280TDNTFVSGNCDVVIG1207KVTLADAGFIKQYGD281FVSGNCDVVIGVNN1208ADAGFIKQYGDCLGD281FVSGNCDVVIGVNNV1209FIKQYGDCLGDDAAR283VIGIVNNTVPDLQP1209FIKQYGDCLGDIAARDLIC284VNNTVVDPLQPELDS1210YGDCLGDIAARDLIC284VVNTVVDPLQPELDS1211LGDIAARDLICAQKF285VYDPLQPELDSFKEE1212AARDLICAQKFNGLT286LQPELDSFKEE1213LICAQKFNGLTVLPP287LDSFKEELDKYFKNH1214QKFNGLTVLPPLLTD288KEELDKYFKNHFD1215GLTVLPPLLTDEMIA289DKYFKNHTSPD1216LPPLLTDEMIAQYTS290KNHTSPDVDLGDISG1219YTSALLAGTIT292DLGDISGINAS1219YTSALLAGTITGGWT293ISGINASVVNIQKEI1220LLAGTITSGWTFGAGA294NASVVNIQKEIRN1221TITSGWTFGAGAALQ295VNIQKEIDRLIN1222GAGAALQIPFAA296KEIDRLNEVAKNLNE1223GAGAALQIPFAMQMA297RLNEVAKNLNESLID1224ALQIPFAMQMAYFFN298VAKNLNESLIDLQEL1	
206LLFNKVTLADAGFIK280TDNTFVSGNCDVVIG281207KVTLADAGFIKQYGD281FVSGNCDVVIGIVNN1208ADAGFIKQYGDCLGD282NCDVVIGIVNNTVYD1209FIKQYGDCLGDIAAR283VIGIVNNTVYDPLQP1210YGDCLGDIAARDLIC284VNNTVYDPLQPELDS1211LGDIAARDLICAQKF285VYDPLQPELDSFKEE1212AARDLICAQKFNGLT286LQPELDSFKEELDKY1213LICAQKFNGLTVLPP287LDSFKEELDKYFKNH1214QKFNGLTVLPPLITD287LDSFKEELDKYFKNH1215GLTVLPPLLTDEMIA289DKYFKNHTSPD1216LPPLLDEMIAQYTS290KNHTSPDVDLG1217LTDEMIAQYTSALLA291SPDVDLGDISGINAS1218MIAQYTSALLAGTIT292DLGDISGINASVNI11219YTSALLAGTITSGWTT293ISGINASVVNIQKEIDRLN1210LLGATTSGWTFGAGALQ294NASVVNIQKEIDRLN1212GAGAALQIPFA295VNIQKEIDRLNEVAK1213GAGAALQIPFA296KEIDRLNEVAKNLNESLID1	
207KVTLADAGFIKQYGD281FVSGNCDVVIGIVNN1208ADAGFIKQYGDCLGD282NCDVVIGIVNNTVYD1209FIKQYGDCLGDIAAR283VIGIVNNTVYDPLQP1210YGDCLGDIAARDLIC284VNNTVYDPLQPELDS1211LGDIAARDLICAQKF285VYDPLQPELDSKEE1212AARDLICAQKFNGLT286LQPELDSFKEE1213LICAQKFNGLTVLPP287LDSFKEELDKY1214QKFNGLTVLPPLITD288KEELDKYFKNH1215GLTVLPPLITD289DKYFKNHTSPD1216LPPLITDEMIA290KNHTSPDVDLGDISG1217LTDEMIAQYTSALLA291SPDVDLGDISGINAS1218MIAQYTSALLAGTIT292DLGDISGINASVVNI1219YTSALLAGTITSGWT293ISGINASVVNIQKEI1211TITSGWTFGAGAALQ295VNIQKEIDRLN1212GWTFGAGAALQIPFA296KEIDRINEVAKNLNE1223GAGAALQIPFA297RLNEVAKNLNESLID1224ALQIFAMQMAYRFN298VAKNLNESLIDLQEL1	
208ADAGFIKQYGDCLGD282NCDVVIGIVNNTVYD209209FIKQYGDCLGDIAAR283VIGIVNNTVYDPLQP283210YGDCLGDIAARDLIC284VNNTVYDPLQPELDS281211LGDIAARDLICAQKF285VYDPLQPELDSFKEE285212AARDLICAQKFNGLT286LQPELDSFKEELDKY287213LICAQKFNGLTVLPP287LDSFKEELDKY287214QKFNGLTVLPPLITD288KEELDKYFKNH215215GLTVLPPLITDEMIA289DKYFKNHTSPDVDLG216216LPPLITDEMIAQYTS290KNHTSPDVDLGDISG217217LTDEMIAQYTSALLA291SPDVDLGDISGINAS218218MIAQYTSALLAGTIT292DLGDISGINASVVNI219219YTSALLAGTITSGWT293ISGINASVVNIQKEI220220LLAGTITSGWTFGAGG294NASVVNIQKEIDRLN221221TITSGWTFGAGAALQ295VNIQKEIDRLN222223GAGAALQIPFA296KEIDRLNEVAKNLNE223224ALQIPFAMQMA298VAKNLNESLIDLQEL298	
209FIKQYGDCLGDIAAR283VIGIVNNTVYDPLQP201210YGDCLGDIAARDLIC284VNNTVYDPLQPELDS281211LGDIAARDLICAQKF285VYDPLQPELDSFKEE282212AARDLICAQKFNGLT286LQPELDSFKEELDKY283213LICAQKFNGLTVLPP287LDSFKEELDKY283214QKFNGLTVLPPLITD288KEELDKYFKNH283215GLTVLPPLITDEMIA289DKYFKNHTSPDVDLG283216LPPLITDEMIAQYTS290KNHTSPDVDLGDISG214217LTDEMIAQYTSALLA291SPDVDLGDISGINAS215218MIAQYTSALLAGTIT292DLGDISGINASVVNI214219YTSALLAGTITGGWT293ISGINASVVNIQKEI215220LLAGTITSGWTFGAGAG294NASVVNIQKEIDRLN214221TITSGWTFGAGAALQ295VNIQKEIDRLN215223GAGAALQIPFA296KEIDRLNEVAKNLNE223224ALQIPFAMQMAYRFN298VAKNLNESLIDLQEL298	
210YGDCLGDIAARDLICImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system211LGDIAARDLICAQKFImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system212AARDLICAQKFNGLTImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system213LICAQKFNGLTVLPPImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system214QKFNGLTVLPPLLTDEImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system215GLTVLPPLLTDEMIAImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system216LPPLLTDEMIAQYTSALLAImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system217LTDEMIAQYTSALLAGTITImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the system218MIAQYTSALLAGTITImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the systemImage: Constraint of the	
211LGDIAARDLICAQKF285VYDPLQPELDSFKEE1212AARDLICAQKFNGLT286LQPELDSFKEELDKY1213LICAQKFNGLTVLPP287LDSFKEELDKYFKNH1214QKFNGLTVLPPLITD288KEELDKYFKNHTSPD1215GLTVLPPLLTDEMIA289DKYFKNHTSPDVDLG1216LPPLLTDEMIAQYTS290KNHTSPDVDLGDISG1217LTDEMIAQYTSALLA291SPDVDLGDISGINAS1218MIAQYTSALLAGTIT292DLGDISGINASVVNI1219YTSALLAGTITSGWT293ISGINASVVNIQKEI1220LLAGTITSGWTFGAG294NASVVNIQKEIDRLN1221TITSGWTFGAGAALQ295VNIQKEIDRLNEVAK1222GWTFGAGAALQIPFA296KEIDRLNEVAKNINE1223GAGAALQIPFAMQMA297RLNEVAKNINESLID1224ALQIPFAMQMAYRFN298VAKNINESLIDLQEL1	
212AARDLICAQKFNGLTImage: Constraint of the system286LQPELDSFKEELDKYImage: Constraint of the system213LICAQKFNGLTVLPP287LDSFKEELDKYFKNHImage: Constraint of the systemImage: Constraint of the system<	
213LICAQKFNGLTVLPPImage: Constraint of the system of	
214QKFNGLTVLPPLLTDImage: Constraint of the system288KEELDKYFKNHTSPDImage: Constraint of the system215GLTVLPPLLTDEMIA289DKYFKNHTSPDVDLGImage: Constraint of the systemImage: Constraint of the system<	
215GLTVLPPLLTDEMIA289DKYFKNHTSPDVDLG210216LPPLLTDEMIAQYTS290KNHTSPDVDLGDISG211217LTDEMIAQYTSALLA291SPDVDLGDISGINAS212218MIAQYTSALLAGTIT292DLGDISGINASVVNI212219YTSALLAGTITGWT293ISGINASVVNIQKEI213210LLAGTITSGWTFGAGA294NASVVNIQKEIDRLN214211TITSGWTFGAGAALQ295VNIQKEIDRLNVAK212221GWTFGAGAALQIPFA296KEIDRLNEVAKNLNE223223GAGAALQIPFAMQMA297RLNEVAKNLNESLID214224ALQIPFAMQMAYRFN298VAKNLNESLIDLQEL215	
216LPPLLTDEMIAQYTS200KNHTSPDVDLGDISG201217LTDEMIAQYTSALLA291SPDVDLGDISGINAS201218MIAQYTSALLAGTIT292DLGDISGINASVVNI201219YTSALLAGTITGSWT293ISGINASVVNIQKEI201220LLAGTITSGWTFGAG294NASVVNIQKEIDRLN201221TITSGWTFGAGAALQ295VNIQKEIDRLN201222GWTFGAGAALQIPFA296KEIDRLNEVAKNLNE201223GAGAALQIPFAMQMA297RLNEVAKNLNESLID201224ALQIPFAMQMAYRFN208VAKNLNESLIDLQEL201	
218MIAQYTSALLAGTIT200292DLGDISGINASVVNI200219YTSALLAGTITSGWT293ISGINASVVNIQKEI200220LLAGTITSGWTFGAG294NASVVNIQKEIDRLN200221TITSGWTFGAGAALQ295VNIQKEIDRLNEVAK200222GWTFGAGAALQIPFA296KEIDRLNEVAKNINE200223GAGAALQIPFAMQMA297RLNEVAKNLNESLID200224ALQIPFAMQMAYRFN208VAKNLNESLIDLQEL200	
219YTSALLAGTITSGWT2001SGINASVVNIQKEI200220LLAGTITSGWTFGAG294NASVVNIQKEIDRLN201221TITSGWTFGAGAALQ295VNIQKEIDRLNEVAK202222GWTFGAGAALQIPFA296KEIDRLNEVAKNINE202223GAGAALQIPFAMQMA297RLNEVAKNLNESLID202224ALQIPFAMQMAYRFN208VAKNLNESLIDLQEL203	
220LLAGTITSGWTFGAG294NASVVNIQKEIDRLN1221TITSGWTFGAGAALQ295VNIQKEIDRLNEVAK1222GWTFGAGAALQIPFA296KEIDRLNEVAKNLNE1223GAGAALQIPFAMQMA297RLNEVAKNLNESLID1224ALQIPFAMQMAYRFN298VAKNLNESLIDLQEL1	
221TITSGWTFGAGAALQ295VNIQKEIDRLNEVAK1222GWTFGAGAALQIPFA296KEIDRLNEVAKNLNE1223GAGAALQIPFAMQMA297RLNEVAKNLNESLID1224ALQIPFAMQMAYRFN298VAKNLNESLIDLQEL1	
222GWTFGAGAALQIPFA296KEIDRLNEVAKNLNE223GAGAALQIPFAMQMA297RLNEVAKNLNESLID2224ALQIPFAMQMAYRFN298VAKNLNESLIDLQEL2	
223 GAGAALQIPFAMQMA 297 RLNEVAKNLNESLID 224 ALQIPFAMQMAYRFN 298 VAKNLNESLIDLQEL	
224 ALQIPFAMQMAYRFN 298 VAKNLNESLIDLQEL	
225 PFAINQINATKENGIGV 299 LINESLIDIQUEGKTE 226 QMAYRFNGIGVTQNV 300 LIDIQUEGKTE	
227 RFNGIGVTQNVLYEN 301 QELGKYEQYIKWPWY	
228 IGVTQNVLYENQKLI 302 KYEQYIKWPWYIWLG	
229 QNVLYENQKLIANQF 303 YIKWPWYIWLGFIAG	
230 YENQKLIANQFNSAI 304 PWYIWLGFIAGLIAI	
231 KLIANQFNSAIGKIQ 305 WLGFIAGLIAIVMVT	
232 NQFNSAIGKIQDSLS 306 IAGLIAIVMVTIMLC	
233 SAIGKIQDSLSSTAS 307 IAIVMVTIMLCCMTS	
234 KIQDSLSSTASALGK 308 MVTIMLCCMTSCCSC	
235 SLSSTASALGKLQDV 309 MLCCMTSCCSCLKGC	
236 TASALGKLQDVVNQN 310 MTSCCSCLKGCCSCG	
237 LGKLQDVVNQNAQAL 311 CSCLKGCCSCGSCCK	

238	QDVVNQNAQALNTLV		312	KGCCSCGSCCKFDED	
239	NQNAQALNTLVKQLS		313	SCGSCCKFDEDDSEP	
240	QALNTLVKQLSSNFG		314	CCKFDEDDSEPVLKG	
241	TLVKQLSSNFGAISS		315	DEDDSEPVLKGVKLH	
			316	DDSEPVLKGVKLHYT	

A. Media



B. S1 peptides





Antigen specific T cells were identified by gating on LIVE/DEAD negative, size (FSC-A vs SSC), doublet negative (FSC-H vs FSC-A), CD3⁺, CD4⁺ or CD8⁺ cells and each individual cytokine. T effector (Teff) cells were defined as CD62L^{low} CD127^{low}, T effector memory (Tem) cells defined as CD62L^{low} CD127^{hi} and T central memory (Tcm) cells defined as CD62L^{hi} CD127^{hi}. T cell subsets were gated within the population of "IFN γ^+ or TNF $\alpha^{+\gamma}$ " responses and are presented after subtraction of the background response detected in the corresponding media stimulated control sample (**A**.) from the S1 (**B**.) or S2 peptide stimulated sample for each mouse, and summing together the response detected to each pool of peptides.